Follow-up program for lung cancer patients treated with radiotherapy
Records outcomes in adults with lung cancer treated with radiation.
Plain-language title generated from the registry record
Registry title: Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation
Key facts
- Where
- Groningen, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung cancer, thymoma or lung metastases who receive radiotherapy, so their results can be followed.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- NSCLC, SCLC-LD (limited disease small cell lung cancer), thymoma, or lung metastases treated with stereotactic radiotherapy
- Earlier treatment
- Patients receive radiotherapy with a dose above 40 Gy (radiotherapy or chemoradiation).
Main reasons for not taking part
- Not meeting the inclusion criteria
Read by machine on 12 November 2026.
Where in Netherlands
- University Medical Center GroningenGroningen, NetherlandsContact: Robin Wijsman, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT02421718
- Record updated
- 29 April 2026
- Original description
Motive:Read full original descriptionShow less
Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation
Motive:
In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients.
Goal:
To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.
A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
Inclusion: Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy); Patients receiving radiotherapy dose > 40 Gy.
Exclusion: Failure to comply with any of the inclusion criteria.